Emergent BioSolutions lands $911 million contract for anthrax vaccine

Emergent BioSolutions has landed a $911 million, five-year follow-on contract for its anthrax vaccine BioThrax

Emergent BioSolutions, a Gaithersburg-based drug developer, has signed a contract with the Centers for Disease Control and Prevention worth up to $911 million over five years to supply more than 29 million doses of its BioThrax anthrax vaccine.

In a notice of intent, the Biomedical Advanced Research and Development Authority said it also planned to order another $100 million-worth of BioThrax.

Emergent, which has a manufacturing facility in Baltimore, will deliver the order within two years of the contract award, expected in the first half of 2017. The company's stock shot up Friday, reaching a high of $33.94 per share and closing at $32.37, up nearly 19 percent.

The new BioThrax orders come on the heels of a September contract with BARDA — which is part of the Department of Health and Human Services — worth up to $1.6 billion for NuThrax, Emergent's next generation anthrax vaccine candidate. The company's anthrax vaccines are manufactured in Michigan.

Emergent has since updated its financial outlook for 2016. The company now projects for 2016 total revenue on a combined basis to $505 million and net income on a combined basis to $45 million.

Its Baltimore facility is one of three in the country designated by federal health officials as a Center for Innovation in Advanced Development and Manufacturing, providing vaccines and treatments that respond to public health emergencies.


Copyright © 2018, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad